Medulloblastoma Clinical Trials

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED
N
Recruiting
  • High Grade Meningioma
  • +4 more
    • Bethesda, Maryland
      National Cancer Institute (NCI)
    2022-04-07
    Apr 7, 2022
    N
    Recruiting
    • Medulloblastoma
    • +4 more
    • La Jolla, California
    • +9 more
    2022-04-07
    Apr 7, 2022
    N
    Completed
    • Diffuse Intrinsic Pontine Glioma
    • +4 more
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      2022-04-07
      Apr 7, 2022
      S
      Recruiting
      • Anaplastic Astrocytoma
      • +55 more
      • Memphis, Tennessee
        St. Jude Children's Research Hospital
      2022-04-01
      Apr 1, 2022
      T
      Recruiting
      • Ependymoma
      • +3 more
      • Augusta, Georgia
        Augusta University, Georgia Cancer Center
      2022-03-20
      Mar 20, 2022
      T
      Recruiting
      • Glioblastoma
      • +3 more
      • Augusta, Georgia
      • +1 more
      2022-03-11
      Mar 11, 2022
      C
      Recruiting
      • Ependymoma
      • +3 more
      • IL13Ralpha2-specific Hinge-optimized 41BB-co-stimulatory CAR Truncated CD19-expressing Autologous T-Lymphocytes
      • Duarte, California
        City of Hope Medical Center
      2022-03-09
      Mar 9, 2022
      G
      No longer available
      • Neuroblastoma
      • +5 more
      • eflornithine HCl
      • Charlotte, North Carolina
        Levine Children's Hospital
      2022-03-03
      Mar 3, 2022
      R
      Not yet recruiting
      • High Grade Glioma
      • +12 more
      • LUTATHERA® (Lutetium Lu 177 dotatate)
      • Aurora, Colorado
      • +8 more
      2022-03-03
      Mar 3, 2022
      S
      Recruiting
      • Brain Tumor
      • Medulloblastoma
      • Memphis, Tennessee
        St.Jude Children's Research Hospital
      2022-03-07
      Mar 7, 2022
      P
      Active, not recruiting
      • Medulloblastoma
      • +7 more
      • SurVaxM for patients with relapsed or progressive MB, HGG or ependymoma ages ≥10 and ≤21 years
      • +2 more
      • Buffalo, New York
        Roswell Park Comprehensive Cancer Center
      2022-02-15
      Feb 15, 2022
      C
      Recruiting
      • Central Nervous System Neoplasms
      • +22 more
      • Bethesda, Maryland
        National Institutes of Health
      2022-03-01
      Mar 1, 2022
      S
      Recruiting
      • Central Nervous System Tumor, Pediatric
      • +8 more
      • HER2-specific chimeric antigen receptor (CAR) T cell
      • Seattle, Washington
        Seattle Children's Hospital
      2022-02-10
      Feb 10, 2022
      U
      Terminated
      • Lymphoma
      • +15 more
      • Charlottesville, Virginia
        University of Virginia
      2022-02-08
      Feb 8, 2022
      U
      Recruiting
      • Medulloblastoma
      • +2 more
      • Specialized Tumor Board Treatment Plan
      • San Diego, California
      • +2 more
      2022-02-22
      Feb 22, 2022
      G
      Active, not recruiting
      • Neuroblastoma
      • +3 more
      • Guided Therapy- Pediatric Gene Analysis Platform
      • Phoenix, Arizona
      • +12 more
      2022-02-16
      Feb 16, 2022
      G
      Active, not recruiting
      • Neuroblastoma
      • +18 more
      • Guided Therapy
      • Little Rock, Arkansas
      • +18 more
      2022-02-16
      Feb 16, 2022
      G
      Active, not recruiting
      • Neuroblastoma
      • Medulloblastoma
      • San Diego, California
      • +14 more
      2022-02-16
      Feb 16, 2022
      N
      Recruiting
      • Medulloblastoma
      • Central Nervous System Embryonal Tumors
      • Birmingham, Alabama
      • +61 more
      2022-02-16
      Feb 16, 2022
      S
      Recruiting
      • Central Nervous System Tumor, Pediatric
      • +8 more
      • EGFR806-specific chimeric antigen receptor (CAR) T cell
      • Seattle, Washington
        Seattle Children's Hospital
      2022-02-09
      Feb 9, 2022
      U
      Active, not recruiting
      • Medulloblastoma
      • Neuroectodermal Tumor
      • TTRNA-xALT
      • TTRNA-DCs
      • Los Angeles, California
      • +2 more
      2022-01-07
      Jan 7, 2022
      B
      Recruiting
      • Neuroendocrine Tumors
      • +15 more
      • 68Ga-DOTATOC PET/CT
      • 18F-FDG PET/CT
      • Vancouver, British Columbia, Canada
        BC Cancer
      2022-02-02
      Feb 2, 2022
      C
      Active, not recruiting
      • Desmoplastic/Nodular Medulloblastoma
      • +4 more
      • Birmingham, Alabama
      • +172 more
      2022-01-04
      Jan 4, 2022